№ lp_1_2_38091
File format: docx
Character count: 26651
File size: 50 KB
This document outlines the procedures for licensed pharmacists to administer long-acting injectable antipsychotics to patients in collaboration with physicians under specific guidelines established by Connecticut law.
Year:
2010
Region / City:
Connecticut
Subject:
Pharmaceutical practice, Collaborative practice agreements, Antipsychotic therapy
Document Type:
Legal agreement, Clinical protocol
Organization / Institution:
Connecticut Department of Consumer Protection, University of Connecticut School of Pharmacy
Author:
C. Caley, PharmD, BCPP, Clinical Professor
Target Audience:
Pharmacists, Physicians, Healthcare providers in Connecticut
Effective Date:
October 1, 2010
Date of Approval:
Not specified
Date of Review:
Annual review completed
Date of Modification:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Subject:
High Dose Antipsychotic Monitoring
Document Type:
Medical Form
Institution:
Oxford Health
Target Audience:
Healthcare professionals
Version number:
6.0
Approved by:
Medicines Committee
Ratified by:
Medicines Committee
Date ratified:
June 2023
Original author:
Luton & Bedfordshire Lead Pharmacist
Executive Director lead:
Chief Medical Officer
Implementation Date:
July 2023
Last Review Date:
June 2023
Next Review Date:
June 2026
Services:
Trustwide, Mental Health and LD, Community Health Services
Type of document:
Policy
Scope:
Long-acting antipsychotic injections, typical and atypical
Target audience:
Clinicians, pharmacists, mental health services staff
Document structure:
Includes guidance on initiation, choice, and monitoring of depot injections, adverse effect reporting, and appendices with forms and rating scales
Year:
2011-2014
Region / city:
Oxford, United Kingdom
Topic:
Aripiprazole treatment, antipsychotic induced hyperprolactinaemia
Document type:
Clinical trial report
Organization / institution:
University of Oxford
Author:
Guy Goodwin, Valeria Frighi, Matthew Stephenson, Alireza Morovat, Anthony James
Target audience:
Medical professionals, researchers, healthcare providers
Period of validity:
2011-2014
Approval date:
Not specified
Date of changes:
Not specified
Study initiation date:
27/4/2011
Date of termination:
31/12/2014
Date of current report:
4/8/2016
Principal Investigator:
Guy Goodwin
Clinical Coordinator and contact person:
Dr. Valeria Frighi
Study centers:
University of Oxford, Oxford Health NHS Foundation Trust, Oxfordshire Learning Disability NHS Trust
Diagnosis:
Severe mental illness and/or learning disability with antipsychotic induced hyperprolactinaemia
Test drug:
Aripiprazole (Abilify)
Study drug dose:
2.5-30 mg daily planned, 1.5-10 mg used
Follow-up duration:
Median 6.1 months
Evaluation criteria:
Efficacy (prolactin reduction, menses normalization, testosterone normalization), Safety (metabolic parameters, psychiatric/neurological symptoms)
Safety results:
No unexpected adverse reactions, known adverse reactions occurred in 2 patients
Efficacy results:
Significant reduction of prolactin in patients on risperidone or paliperidone, restoration of normal gonadal function
Statistical methods:
Mann-Whitney U test, paired t-tests
Context:
Clinical trial report on the efficacy and safety of adjunctive aripiprazole treatment for hyperprolactinaemia in patients with severe mental illness and learning disabilities
Year:
2024
Region / City:
Massachusetts
Topic:
Long-Acting Injectable Antipsychotic Medications
Document Type:
MassHealth Drug List Update
Institution:
MassHealth
Author:
MassHealth
Target Audience:
Healthcare providers, inpatient psychiatric service providers
Effective Period:
May 15, 2024
Approval Date:
May 15, 2024
Update Date:
Ongoing updates
Applicable Policy:
Long-Acting Injectable Antipsychotic Medication Payment and Reimbursement Policy
J-Codes:
J0401, J0402, J1631, J1943, J1944, J2358, J2426, J2427, J2428, J2680, J2794, J2798, J2799, J2801
Billing Instructions:
Available on the MassHealth website
Year:
2005-2015
Region:
The Netherlands
Topic:
Pediatric psychopharmacology
Document type:
Research article
Institution:
Erasmus Medical Centre, University of Groningen
Authors:
Sanne M. Kloosterboer, Catharina C.M. Schuiling-Veninga, Jens H.J. Bos, Luuk J. Kalverdijk, Birgit C.P. Koch, Gwen C. Dieleman, Manon H.J. Hillegers, Bram Dierckx
Funding:
The Netherlands Organisation for Health Research and Development (ZonMW), grant 836041011
Target audience:
Healthcare professionals, researchers
Data source:
IADB.nl community pharmacy prescription database
Study population:
Youths aged 0-19 years
Outcome measures:
Prevalence, incidence, dosages, duration of antipsychotic use, prior psychotropic medication
Key findings:
Stabilization of usage rates, decrease in dosages and duration, one in eight youths used antipsychotics ≥4 years, boys had longer median usage than girls
Type of source:
Peer-reviewed scientific article
Type of document:
Pharmaceutical Benefits Advisory Committee (PBAC) submission and assessment report
Medicine:
Aripiprazole long-acting injectable (AOM)
Dosage forms/strengths:
Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe; Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe
Brand:
Abilify Maintena
Sponsor:
Lundbeck Australia Pty Ltd
Purpose of submission:
Request for General Schedule Authority Required (STREAMLINED) PBS listing of AOM pre-filled syringe dose form
Indication:
Treatment of schizophrenia
Comparator:
AOM modified release injection vial kit (therapeutic vial kits)
Regulatory status:
TGA registered 7 May 2018 for acute and maintenance treatment of schizophrenia in adults and maintenance treatment of bipolar I disorder (monotherapy)
Previous PBAC consideration:
400 mg AOM PFS recommended July 2018; recommendation rescinded March 2023
Pricing basis:
Cost-minimisation versus AOM vial kit with equivalent pricing (no price premium)
Price levels referenced:
DPMQ, PTP, AEMP (current as of 1 June 2025)
Estimated PBS usage:
400,000 to <500,000 scripts over first six years (Year 1 10,000–<20,000; Year 6 100,457)
Indication listing conditions:
Authority Required (Streamlined); prescriber types include medical practitioners and nurse practitioners; general schedule (Code GE)
Version number:
6.0
Approved by:
Medicines Committee
Ratified by:
Medicines Committee
Date ratified:
June 2023
Original author:
Luton & Bedfordshire Lead Pharmacist
Executive Director lead:
Chief Medical Officer
Implementation Date:
July 2023
Last Review Date:
June 2023
Next Review Date:
June 2026
Services:
Trustwide, Mental Health and LD, Community Health Services
Type of document:
Policy
Scope:
Long-acting antipsychotic injections, typical and atypical
Target audience:
Clinicians, pharmacists, mental health services staff
Document structure:
Includes guidance on initiation, choice, and monitoring of depot injections, adverse effect reporting, and appendices with forms and rating scales
Document type:
Shared care protocol
Medicine:
Paliperidone palmitate long-acting injection
Indication:
Maintenance treatment of schizophrenia
Population:
Adults aged 18 years and over
Healthcare setting:
Secondary and primary care
Intended users:
NHS healthcare professionals
Initiation of treatment:
Secondary care mental health services
Shared care commencement:
After approximately 12 weeks when dose is optimised
Dosage forms:
1-monthly, 3-monthly and 6-monthly long-acting injections
Renal impairment restriction:
Not recommended in moderate or severe renal impairment (creatinine clearance <50 ml/min)
Version:
v4.0
Replaces version:
v3.0
Clinical content last reviewed:
January 2024
Next review date:
June 2026
Approving bodies:
GM CRG, GMMMG, CEGC
Approval dates:
14 May 2024; 13 June 2024; 20 June 2024
Geographical scope:
NHS Greater Manchester
Usage restriction:
Non-commercial, non-marketing use only
Year:
not specified
Language:
English
Topic:
HIV-1 treatment
Therapeutic regimen:
Long-acting injectable antiretroviral therapy
Medication:
Cabenuva (cabotegravir and rilpivirine)
Drug classes:
Integrase strand transfer inhibitor; non-nucleoside reverse transcriptase inhibitor
Route of administration:
Intramuscular gluteal injection
Dosing schedules:
Every 4 weeks; every 8 weeks
Target population:
Adults with HIV-1 infection
Eligibility criteria:
Virologically suppressed patients without relevant drug resistance
Exclusion criteria:
Pregnancy, breastfeeding, specific drug interactions, hypersensitivity
Monitoring requirements:
HIV viral load, CMP, CBC
Clinical setting:
Clinic-administered therapy
Healthcare roles:
Provider, case manager, registered nurse, pharmacy
Regulatory reference:
FDA labeling
Source adaptation:
Ward 86 Long-Acting Injectable ARV Protocol
Year:
2021
Region / City:
United States
Subject:
Medicine, Pharmacology
Document Type:
Drug Information
Agency / Institution:
Food and Drug Administration (FDA)
Author:
FDA
Target Audience:
Healthcare professionals, physicians, pharmacists
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Revisions:
Not specified
Year:
2023
Region / City:
Global
Topic:
Pharmacology, Psychiatry
Document Type:
Medical Guidelines
Organization / Institution:
Unspecified
Author:
Unspecified
Target Audience:
Healthcare Professionals, Psychiatrists
Duration of Validity:
Indefinite
Approval Date:
Unspecified
Date of Changes:
Unspecified
Year:
2024
Region:
Massachusetts, USA
Subject:
Healthcare billing, Antipsychotic medications
Document Type:
Policy / Instruction
Organization:
MassHealth
Audience:
In-state acute inpatient hospital providers
Effective Date:
5/15/2024
Reference:
Sections 5.B.4.g of the MassHealth Acute Hospital Request for Applications
Medication Covered:
Long-Acting Injectable (LAI) Antipsychotics
Billing Codes:
National Drug Code (NDC), HCPCS
Submission Requirements:
Professional claims (Claim Types M and B), Direct Data Entry for IC drugs, invoice attachment from distributor/manufacturer
Payment Methodology:
Fee schedule in 101 CMR 317.00 or Individual Consideration (IC)
Documentation:
Attachments via Provider Online Service Center (POSC)
Compliance Notes:
Failure to follow instructions may result in inaccurate payment
Instruction Updates:
May be updated from time to time
Year:
2024
Region / City:
Massachusetts
Topic:
Long-Acting Injectable Antipsychotic Medications
Document Type:
MassHealth Drug List Update
Institution:
MassHealth
Author:
MassHealth
Target Audience:
Healthcare providers, inpatient psychiatric service providers
Effective Period:
May 15, 2024
Approval Date:
May 15, 2024
Update Date:
Ongoing updates
Applicable Policy:
Long-Acting Injectable Antipsychotic Medication Payment and Reimbursement Policy
J-Codes:
J0401, J0402, J1631, J1943, J1944, J2358, J2426, J2427, J2428, J2680, J2794, J2798, J2799, J2801
Billing Instructions:
Available on the MassHealth website
Type of document:
Pharmaceutical Benefits Advisory Committee (PBAC) submission and assessment report
Medicine:
Aripiprazole long-acting injectable (AOM)
Dosage forms/strengths:
Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe; Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe
Brand:
Abilify Maintena
Sponsor:
Lundbeck Australia Pty Ltd
Purpose of submission:
Request for General Schedule Authority Required (STREAMLINED) PBS listing of AOM pre-filled syringe dose form
Indication:
Treatment of schizophrenia
Comparator:
AOM modified release injection vial kit (therapeutic vial kits)
Regulatory status:
TGA registered 7 May 2018 for acute and maintenance treatment of schizophrenia in adults and maintenance treatment of bipolar I disorder (monotherapy)
Previous PBAC consideration:
400 mg AOM PFS recommended July 2018; recommendation rescinded March 2023
Pricing basis:
Cost-minimisation versus AOM vial kit with equivalent pricing (no price premium)
Price levels referenced:
DPMQ, PTP, AEMP (current as of 1 June 2025)
Estimated PBS usage:
400,000 to <500,000 scripts over first six years (Year 1 10,000–<20,000; Year 6 100,457)
Indication listing conditions:
Authority Required (Streamlined); prescriber types include medical practitioners and nurse practitioners; general schedule (Code GE)
Version:
5
Agreed Date:
16/10/2024
Review Date:
16/10/2026
Geographic Scope:
Pan-London
Healthcare Setting:
Community setting
Clinical Area:
Palliative care
Document Type:
Medication authorisation and administration record
Medication Routes:
Subcutaneous injection; Intramuscular injection; Continuous subcutaneous infusion
Medication Use:
As required (PRN); Regular dosing; Crisis and emergency use
Patient Population:
Community patients receiving injectable symptom control medication
Responsible Professionals:
Authorising clinicians (GMC/NMC/GPhC registered)
Associated System:
NHS
Content Sections:
PRN injection charts; syringe pump authorisation charts; crisis and emergency injection records; regular dose injection records; controlled drug stock balance charts
Review Statement:
Subject to ongoing review to reflect emerging evidence
Year:
not specified
Language:
English
Topic:
HIV-1 treatment
Therapeutic regimen:
Long-acting injectable antiretroviral therapy
Medication:
Cabenuva (cabotegravir and rilpivirine)
Drug classes:
Integrase strand transfer inhibitor; non-nucleoside reverse transcriptase inhibitor
Route of administration:
Intramuscular gluteal injection
Dosing schedules:
Every 4 weeks; every 8 weeks
Target population:
Adults with HIV-1 infection
Eligibility criteria:
Virologically suppressed patients without relevant drug resistance
Exclusion criteria:
Pregnancy, breastfeeding, specific drug interactions, hypersensitivity
Monitoring requirements:
HIV viral load, CMP, CBC
Clinical setting:
Clinic-administered therapy
Healthcare roles:
Provider, case manager, registered nurse, pharmacy
Regulatory reference:
FDA labeling
Source adaptation:
Ward 86 Long-Acting Injectable ARV Protocol
Year:
2018
Region / City:
Global
Topic:
Family Planning
Document Type:
Training Material
Institution:
CCP, WHO
Author:
Not specified
Target Audience:
Healthcare professionals, trainees
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Title:
Polysulfated Glycosaminoglycan (Adequan)
Active ingredient:
Polysulfated glycosaminoglycan (primarily chondroitin sulfate)
Brand name:
Adequan®
Source of substance:
Extracted from bovine tracheal tissue
Pharmaceutical form:
Injectable solution
Route of administration:
Intramuscular injection
Indications:
Arthritis; Feline lower urinary tract disease
Target species:
Dogs; Cats; Horses
Dosage regimen for arthritis:
Twice weekly for 4 weeks; maximum of eight injections
Pharmacological properties:
Cartilage matrix support; Anti-inflammatory activity; Promotion of joint fluid production
Contraindications:
Known bleeding disorders
Precautions:
Use with caution in patients with kidney disease; Not studied in pregnant or lactating animals
Adverse effects reported:
Injection site pain; Diarrhea; Increased bleeding tendency
Drug interactions:
None known
Related human comparison:
Pentosan polysulfate sodium in interstitial cystitis
Type of document:
Veterinary drug information sheet
Year:
2026
Region / City:
Not specified
Subject:
Pharmaceutical calculations, drug reconstitution
Document Type:
Educational worksheet
Institution / Organization:
Pharmacy education or training program
Author:
Not specified
Target Audience:
Pharmacy students or healthcare trainees
Period of validity:
2026
Date of preparation:
2026-02-27
Drug types covered:
Cefazolin, Ampicillin/Sulbactam, Amoxicillin, Ceftriaxone, Penicillin, Vancomycin, Zosyn, Streptomycin, Cefepime, Ceftazidime, Timentin, IVIG
Measurement units:
mL, g, mg/mL, MU
Application context:
Intravenous and oral drug reconstitution, dose calculation
Year:
2021
Region / City:
Global
Topic:
Progestin-Only Injectable Contraceptives
Document Type:
Training Manual
Organization:
Family Planning Training Resource
Author:
Unknown
Target Audience:
Health providers, facilitators, and trainers
Effective Period:
Ongoing
Approval Date:
Unknown
Modification Date:
Unknown